Day One Biopharmaceuticals, Inc. (: DAWN)

Day One Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life threatening diseases. The company concentrates on pediatric and adult oncology with a lead product OJEMDA which is the brand name for tovorafenib an oral brain penetrant RAF kinase inhibitor approved for relapsed or refractory pediatric low grade glioma. OJEMDA received accelerated approval from the FDA in April 2024 and is marketed as a once weekly tablet or oral suspension for patients six months of age and older. Beyond its approved product the company advancing a pipeline that includes Emi-Le an antibody drug conjugate targeting B7-H4 for adenoid cystic carcinoma and DAY301 an antibody drug conjugate targeting PTK7 for various solid tumors. Day One's strategy emphasizes identifying acquiring and developing first in class or best in class medicines for childhood and adult cancers with high unmet need. The firm leverages its expertise in pediatric oncology to guide clinical development and regulatory interactions while pursuing partnerships that expand global reach.

Revenue is generated primarily from product sales of OJEMDA in the United States. The company also earns revenue from licensing agreements that provide upfront payments milestone payments and royalties. Under the Ipsen license agreement Day One received an upfront fee of $70.8 million and is eligible for up to approximately $375.0 million in commercial launch and sales based milestone payments plus tiered double digit royalties on net sales of tovorafenib outside the United States. The MabCare license agreement involved an upfront payment of $55.0 million and could require additional payments up to $1,132.0 million based on development regulatory and commercial milestones plus low to mid single digit royalties on net sales of DAY301 outside Greater China. The XOMA license agreement relating to the VIRACTA portfolio provides milestone payments and royalties on OJEMDA sales. In addition Day One may receive future milestone payments from other collaborations and retains rights to collect royalties on any future product that reaches commercialization. The firm relies on third party manufacturers for active pharmaceutical ingredients drug product packaging and distribution to support both clinical and commercial supply.

Day One Biopharmaceuticals holds a differentiated position in the oncology market by focusing on brain penetrant RAF inhibition and novel antibody drug conjugates for underserved tumor types. Its lead product OJEMDA is the first systemic therapy for pediatric low grade glioma with once weekly dosing and has received breakthrough therapy orphan drug and rare pediatric disease designations from the FDA. The drug addresses a population where over half of pediatric low grade glioma cases are driven by RAF alterations and no consensus standard of care exists for many patients. Competitors in the RAF inhibitor space include vemurafenib dabrafenib and encorafenib which are type I inhibitors limited to BRAF V600 altered tumors and can cause paradoxical activation in wild type RAF cells. Day One's molecule inhibits both monomeric and dimeric RAF avoiding paradoxical activation which gives it an advantage over those competitors. In the antibody drug conjugate arena the company faces competition from other ADCs targeting PTK7 or B7 H4 but its exclusive worldwide rights for DAY301 outside Greater China and the acquired Emi Le asset provide a distinct edge. The firm's pipeline is supported by ongoing clinical programs such as the FIREFLY 2 Phase 3 trial evaluating tovorafenib as front line therapy in pediatric low grade glioma and the Phase 1b study of DAY301 in advanced solid tumors. Additionally the NCCN guidelines have included tovorafenib as a category 2a option for recurrent or progressive BRAF altered disease underscoring its emerging role in treatment algorithms. These factors collectively position Day One as a specialized innovator in niche oncology segments with limited direct competition.

The company serves hospitals specialty clinics and pediatric and adult oncology centers that treat patients with relapsed or refractory pediatric low grade glioma. Specific customer names are not disclosed in the filing but the customer base includes academic medical centers community hospitals and specialty pharmacy networks. In the United States Day One maintains a focused sales team of approximately eighteen representatives calling on about two hundred accounts that cover the majority of pediatric low grade glioma treaters. Outside the United States the Ipsen partnership handles commercialization granting access to established hospital networks oncology clinics and government reimbursement systems in Europe Asia Latin America and other regions. For its pipeline candidates Day One targets adult and pediatric oncologists treating solid tumors such as ovarian cancer non small cell lung cancer triple negative breast cancer and adenoid cystic carcinoma. The firm also engages with patient advocacy groups and research consortia to inform trial design and improve access to investigational therapies. These interactions help build relationships with prescribing physicians and support future product launch efforts.